bisoprolol (zebeta) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life.   NCATS

Chemistry

  • SMILES: CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1
  • InChIKey: VHYCDWMUTMEGQY-UHFFFAOYSA-N
  • Mol. Mass: 325.45
  • ALogP: 2.37
  • ChEMBL Molecules:
    bisoprolol  
    bisoprolol fumarate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1796 - $0.4603

Australia

$0.1869 - $0.4774
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(+-)-1-((alpha-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol | bipranix | bisoprolol | bisoprolol fumarate | bisoprolol fumarate and hydrochlorothiazide | bisoprolol hemifumarate | bisoprolol - hydrochlorothiazide | bisoprolol, hydrochlorothiazide drug combination | bisoprololum | cardicor | cl-297939 | concor | congescor | emcor | emcor ls | emd-33512 | emd-33-512 | isoten mitis | maxsoten | monocor | (rs)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol | soloc | soprol | vivacor | zebeta | ziac

Organizations (116)

Research & Development (101)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (1)


 

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Angina, Stable (Phase 4)

Aortic Aneurysm, Abdominal (Phase 1)

Aortic Valve Stenosis (Phase 4)

Atrial Fibrillation (Phase 4)

Blood Loss, Surgical (Phase 1)

Blood Pressure (Phase 4)

Breast Neoplasms (Phase 3)

Cardiomyopathy, Dilated (Phase 2/Phase 3)

Cardiotoxicity (Phase 3)

Cardiovascular Diseases (Phase 3)

Chagas Cardiomyopathy (Phase 3)

Coronary Artery Bypass (Phase 4)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus (Phase 2/Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Essential Hypertension (Phase 4)

Familial Primary Pulmonary Hypertension (Phase 1/Phase 2)

Fasting (Phase 1)

General Surgery (Phase 1)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Heart Rate (Early Phase 1)

Hypertension (Phase 4)

Hypertension, Renal (Phase 4)

Insulin Resistance (Phase 4)

Metabolic Syndrome (Phase 4)

Muscular Dystrophy, Duchenne (Phase 2/Phase 3)

Myocardial Infarction (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

Pharmacogenetics (Phase 4)

Pharmacokinetics (Phase 1)

Pheochromocytoma (Phase 2)

Postural Orthostatic Tachycardia Syndrome (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Ventricular Dysfunction, Left (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 71
  • # of Trial Organizations: 101

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue